Dogwood Therapeutics announced its Q3 2026 financial results and completion of the Phase 2b trial for Halneuron, a non-opioid drug targeting chemotherapy-induced neuropathic pain (CINP). The company enrolled 239 patients in the trial and expects to release top-line results in November 2026. A long-term extension study with 95 patients is ongoing, assessing pain reduction over three months. Dogwood also secured a $5 million private placement to support Phase 3 preparations. The company reported a net loss of $4.9 million for Q3 2026, improved from $15.7 million in Q3 2025, with operational funds expected to last through Q1 2027. Halneuron has FDA fast track status and could become the first approved treatment for CINP if successful.
Dogwood Therapeutics' Q3 2026 financial results provide context for readers following biotech news. For readers following the Health sector, here is Pluang's market snapshot as of Nov 05, 2026 19:42 WIB: Of 150 priced Health-sector US stocks tradable on Pluang, 87 rose and 56 fell today. Notable movers include LFST at USD 14.99 with a 1-day change of +5.49%, ALMS at USD 6.20 with a 1-day change of -5.34%, and NVAX at USD 11.21 with a 1-day change of +5.31% and Pluang order activity showing 16% Sell and 84% Buy, with a typical hold time of 60 days.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
